Panel Endorses Samska, Infers Clinical Benefit For The Hyponatremia Drug

An FDA advisory panel endorsed Otsuka Pharmaceuticals' Samska (tolvaptan) for hyponatremia June 25 even though the sponsor's post-hoc analysis of a surrogate endpoint did not clearly prove the drug's clinical benefit